Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax in R/R CLL or SLL
NCT05479994Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Oct 2022
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonrotoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by BeiGene. Primary endpoint: Overall Response Rate as assessed by the Independent Review Committee at 2 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05479994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479994.